TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02152579
Drug: Isosorbide-5-mononitrate
Normalized name: Isosorbide-5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
Study: NCT05240404
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: toripalimab treatment (240mg intravenously every 3 weeks) started on day 3 after ablation for six months
Study: NCT00486694
Drug: Sulfadoxine-pyrimethamine + artesunate
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00486694
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01002755
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT00702403
Drug: nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00702403
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT02691299
Drug: Fruquintinib
Normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
Study: NCT01204476
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01204476
Drug: Octreotide Acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IM
Study: NCT01769040
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550 mg two times daily for 28 days
Study: NCT01341600
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
Study: NCT01341600
Drug: Omeprazole/Clopidogrel
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
Study: NCT02629692
Drug: Vodobatinib (K0706) capsules
Normalized name: Vodobatinib
DrugBank: Vodobatinib (DB17141)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Vodobatinib (K0706) capsules in single ascending doses.~Part B: Oral Vodobatinib (K0706) capsules in multiple ascending doses, once daily.~Part C: Oral Vodobatinib (K0706) capsules at recommended phase 2 dose of 174 mg, once daily.
Study: NCT00102674
Drug: cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03281954
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.~Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.~+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.~Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose.
Study: NCT00056030
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01188694
Drug: Psychotherapy plus Methylene Blue, USP
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
Study: NCT01290042
Drug: AMG 181
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
Study: NCT00393991
Drug: Fluticasone propionate/formoterol fumarate 100/10
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00393991
Drug: Fluticasone propionate 100
Normalized name: FLUTICASONE PROPIONATE 100MCG INHL,ORAL,DISKUS,60
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT00393991
Drug: Formoterol fumarate 10
Normalized name: FORMOTEROL FUMARATE 10MCG/ML SOLN,INH,2ML
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
Study: NCT02943733
Drug: TAS-102
Normalized name: TAS-102
DrugBank: TAS-102 (DB08937)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-metabolite agent, taken orally.
Study: NCT02943733
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral chemotherapy drug.
Study: NCT02943733
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim provides growth factor support in multiple doses. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study: NCT02943733
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim provides growth factor support in a single dose. It stimulates bone marrow to create neutrophils for patients undergoing chemotherapy.
Study: NCT00545857
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone daily; dose varies with size
Study: NCT01104636
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: varenicline tablets prescribed as per local German SmPC for 12 weeks duration
Study: NCT05525156
Drug: aspirin enteric coated tablet 75 mg
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: blister packaged enteric coated tablet of 75 mg aspirin taken once daily for 24 weeks in addition to the conventional antiretroviral drugs
Study: NCT00452075
Drug: erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg daily
Study: NCT02821156
Normalized name: Banana
DrugBank: Banana (DB10505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Nitric Oxide with monitoring by EZ-KINOX device
Study: NCT01162473
Drug: Milk Protein Powder
Normalized name: milk protein concentrate
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk protein powder will be administered in incremental doses during the desensitization protocol.
Study: NCT04671563
Drug: Tenofovir Disoproxil Fumarate 300 MG
Normalized name: tenofovir disoproxil fumarate 300 MG
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One tablet of Viproof Film Coated Tablets or Viread Tablets will be orally administrated with 240 mL of water in the morning.
Study: NCT00004640
Drug: Chlorhexidine rinse
Normalized name: chlorhexidine Mouthwash [Denti-Rinse]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: chlorhexidine solution on tooth loss in low income
Study: NCT00057759
Drug: sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03402191
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine for thalassemia with pulmonary hypertension
Study: NCT03402191
Drug: Sildenafil
Normalized name: Sildenafil
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil for thalassemia with pulmonary hypertension
Study: NCT01295944
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.
Study: NCT01295944
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
Study: NCT00092820
Drug: MK0653, ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02108756
Drug: L-pantoprazole sodium
Normalized name: Pantoprazole Sodium
DrugBank: Pantoprazole (DB00213)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 injection L-pantoprazole sodium (40mg), Bid
Study: NCT01001767
Drug: Lovaza
Normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovaza one gram twice a day for 24 weeks
Study: NCT00276068
Drug: topical lidocaine + oral desipramine, and/or placebo
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00292864
Drug: SNS-032 Injection
Normalized name: sn-3-GPC
DrugBank: SNS-032 (DB05969)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02515968
Drug: Desflurane
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
Study: NCT02515968
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01729754
Drug: Tildrakizumab 200 mg
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
Study: NCT01729754
Drug: Tildrakizumab 100 mg
Normalized name: tildrakizumab 100 mg/mL subcutaneous solution
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
Study: NCT01729754
Drug: Tildrakizumab Placebo
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo to tildrakizumab administered SC
Study: NCT01729754
Drug: Etanercept Placebo
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Matching placebo to etanercept administered SC
Study: NCT01729754
Drug: Etanercept 50 mg
Normalized name: etanercept 50 MG/ML
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept 50 mg administered SC
Study: NCT00734279
Drug: Leuprolide Acetate - Early Puberty Leuprolide Visit
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
Study: NCT00734279
Drug: Ganirelix - Early Puberty Ganirelix Visit
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
Study: NCT00734279
Drug: Ganirelix - Delayed Puberty Ganirelix Visit
DrugBank: Ganirelix (DB06785)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
Study: NCT00734279
Drug: Leuprolide Acetate- Delayed Puberty Leuprolide Visit
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
Study: NCT02452762
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00690014
Drug: probenecid
Normalized name: Probenecid
DrugBank: Probenecid (DB01032)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg q 6 hrs
Study: NCT01121380
Drug: BL-1021
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.~Dosage:~Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 \& 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results.
Study: NCT02637700
Drug: Intravenous Immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
Study: NCT00002733
Drug: cimetidine
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01238692
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:~Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL).
Study: NCT01254227
Drug: Deferasirox and Deferoxamine
DrugBank: Deferoxamine (DB00746)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01985581
Drug: Guanfacine extended release
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03619187
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ivabradine will be provided in bottles (60 tablets per bottle) labeled ivabradine 5 mg and ivabradine 7.5 mg. The 2.5 mg dose of ivabradine will be achieved by subjects splitting the 5 mg tablets into equal halves.
Study: NCT00772772
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
Study: NCT03232281
Drug: Triptorelin Pamoate PR 3-month
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
Study: NCT03232281
Drug: Triptorelin Acetate PR 1-month
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
Study: NCT02338960
Drug: Bremelanotide
Normalized name: Bremelanotide
DrugBank: Bremelanotide (DB11653)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
Study: NCT02981342
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02981342
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered IV
Study: NCT01629368
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple doses of carbamazepine
Study: NCT00408967
Drug: Tucotuzumab celmoleukin (EMD 273066)
Normalized name: Emdisterone
DrugBank: Tucotuzumab celmoleukin (DB15402)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01365507
Drug: insulin degludec/insulin aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
Study: NCT01614990
Drug: Macimorelin
Normalized name: Macimorelin
DrugBank: Macimorelin (DB13074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
Study: NCT02255500
Drug: Bupivacaine FNB
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
Study: NCT02255500
Drug: EXPAREL Infiltration
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
Study: NCT01908543
Drug: Ferrous sulphate 200mg oral tablet
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by mouth
Study: NCT04254978
Drug: Bomedemstat
Normalized name: Bomedemstat
DrugBank: Bomedemstat (DB17234)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT00099125
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00099125
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01798576
Drug: Pegylated Interferon alfa-2a
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
Study: NCT02520388
Drug: HLD200 methylphenidate hydrochloride (MPH) Capsules
Normalized name: Methylphenidate Hydrochloride Extended-Release Capsules
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HLD200 Doses: 40, 60 or 80 mg
Study: NCT04560686
Drug: Bintrafusp Alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01740258
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01740258
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01479764
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
Study: NCT01479764
Drug: Neostigmine
Normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: neostigmine, per usual practice
Study: NCT01479764
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glycopyrrolate per usual practice
Study: NCT03519997
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembroluzumab 200mg IV once every 3 weeks
Study: NCT03519997
Drug: Bavituximab
Normalized name: Bavituximab
DrugBank: Bavituximab (DB05136)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bavituximab 3mg/kg IV weekly
Study: NCT04170088
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid intradermal injections were used for treatment of melasma
Study: NCT01814865
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1000 mg PO OD x 2 weeks
Study: NCT01814865
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg PO OD x 2 weeks
Study: NCT01510119
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03756298
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab is 1,200 mg iv. administered every 3 weeks for 8 cycles with capecitabine (2,000mg/m2/day, day 1-14, every 3 weeks for 8 cycles)
Study: NCT02245256
Drug: Precedex
Normalized name: Precedex
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: infusion of 0.1mcg/kg/hr of precedex
Study: NCT00996879
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Syrup, Oral, 5 mg, Single dose, 2 days
Study: NCT02541071
Drug: Yohimbine
Normalized name: YOHIMBINE
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02541071
Drug: Clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02476968
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.~Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.~Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water.